삼원계를 통한 페북소스타트 고체분산체 개발 및 평가

• 영문명: Development and Evaluation of Febuxostat Solid Dispersion through Ternary System
• 발행기관: 대한약학회
• 저자명: 정하늘(Ha Neul Jung) 최진석(Jin-Seok Choi)
• 간행물 정보: 『약학회지』제68권 제2호(2024년), 105~111쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2024.03.30

영문 초록

Febuxostat is classified as a biopharmaceutical with low solubility in aqueous solution and high intestinal permeability (Biopharmaceutics Classification System [BCS] Class II drug). The solubility of a drug has the characteristic of increasing as pH increases. This study aims to improve the dissolution of febuxostat with Neusilin® US2 and Gelucire®50/13 by a solvent evaporation method. The optimal formulation (solid dispersion, SD1) is developed as a solid dispersion of febuxostat : Gelucire®50/13 : US2®= 1:2:4 (w/w), with a final weight of 280 mg. The dissolution of SD1 in distilled water is 72.0±2.8%, which is 1.67-fold higher than that of the commercial product, Feburic Tab® (43.2±1.8%). The SD1 formulation is believed to have improved dissolution due to changes in physicochemical properties (thermal, interaction, and crystallinity). In conclusion, through the solid dispersion manufacturing method, febuxostat is changed from a crystalline form to an amorphous form in SD1 formulation, and the improved dissolution of febuxostat formulation is developed.

목차

서 론(Introduction)

방 법(Methods)

결과 및 고찰(Results and Discussion)

결 론(Conclusion)

감사의 말씀(Acknowledgment)

Conflict of Interest

References

키워드

Febuxostat Solid dispersion Solvent evaporation method Solubilization Dissolution